Riskpilot← Back to searchSign inGet full accessRevvomed Innovations AB
ABActiveOrg 5594678384Benvedsbacken 1 AResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20240 employees
Revenue 2025
SEK 0
EBITDA margin
—
-1543% vs 2024
Equity ratio
61.7%
Financial strength
Net profit 2025
SEK -132K
-1543% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -132K | -1543% |
| Net profit | SEK -132K | -1543% |
| Total assets | SEK 54K | +219% |
| Equity | SEK 33K | +97% |
| Employees | 0 | — |
Legal name
Revvomed Innovations AB
Org number
5594678384
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15 januari 2024
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Identifiering av nya läkemedelsmål för att vägleda upptäckten av nya medicinska tillämpningar, inklusive men inte begränsat till utveckling av läkemedel och diagnostiska verktyg och därmed förenlig verksamhet.
Address
Benvedsbacken 1 A
Email
robin.loving@revvomed.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | −0 | −0 |
| EBITDA | −8 | −132 |
| Depreciation & amort. | — | — |
| EBIT | −8 | −132 |
| Net financials | — | — |
| Profit before tax | −8 | −132 |
| Tax | — | — |
| Net profit | −8 | −132 |
| Item | 2024 | 2025 |
|---|---|---|
| Total assets | 17 | 54 |
| Equity | 17 | 33 |
| Long-term debt | — | — |
| Short-term debt | — | 21 |
| Total debt | — | 21 |
EBITDA margin
-13218100.0%
This company
15.8%
Market median
-83658961% vs market
20242025
Equity ratio
61.7%
This company
38.2%
Market median
+62% vs market
20242025
Return on equity
-395.8%
This company
18.4%
Market median
-2251% vs market
20242025
Net profit margin
-13218100.0%
This company
8.1%
Market median
-163186520% vs market
20242025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20242025
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20242025
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NN Chief Executive Officer | Chief Executive Officer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Chairman | 2025 | |
| Former (2) | ||
| Deputy Board Member | 2024 – 2025 | |
| Board of Directors | 2024 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Seven and Nine Holding AB
Revvomed Innovations AB Board members of Revvomed Innovations AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nina Nazanin Schiller | Chief Executive Officer | 0 companies |
| Hans Eddy Fabian Löving | Deputy Board Member | 0 companies |
| Hans Robin Löving | Board of Directors | 0 companies |
| Carl Christian Schiller | Chairman | 0 companies |
| Anna Leyla Linnéa Schreiber | Board of Directors | 0 companies |